On April 23, 2026, the U.S. Department of Justice issued a final order rescheduling certain cannabis products from Schedule I to Schedule III under the Controlled Substances Act. The action applies primarily to FDA-approved cannabis-derived drug products and qualifying state-licensed medical cannabis programs, and represents a major change in federal cannabis policy. Notwithstanding its significance, …

Continue reading “The DOJ’s Cannabis Rescheduling Order: Understanding the Next Steps for Operators”